

---

## Collection of Tissues for Isolation of Tumour Infiltrating Lymphocytes – A Process Overview of SOPs

---

Organisation: University of Manchester

Document version number: v.1

Date written: 18.1.22

### End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

Attributions: University of Manchester, iMATCH collaboration, Manchester NHS Foundation Trust, Salford Royal NHS Trust, The Christie NHS Foundation Trust. Professor Richard Edmondson, Dominique Jones, Marcus Price.

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here:

<https://creativecommons.org/licenses/by-nc/4.0/>

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of

Funded by

Coordinated by

the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.

We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents. The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Funded by

Coordinated by

**Division of Cancer Sciences**

## **Collection of tissues for isolation of tumour infiltrating lymphocytes**

### **– a process overview**

#### **Introduction and rationale**

Lymphocytes present in the tumour microenvironment are known as tumour infiltrating lymphocytes (TIL) and are hallmarked by their specific adaptation to target the cancer cell. They thus, potentially, represent a novel therapeutic which, following extraction from the tumour and ex vivo expansion can be administered to a patient as an autologous treatment.

Crucial to this process is the ability to extract TIL from the host tissue which clearly requires tumour tissue to be sampled whilst maintaining both a sterile chain and a traceability pathway.

The following notes provide points to consider when setting up a new pathway and provide signposts to the correct SOPs, which will need modification for each individual pathway.

#### **Research vs therapeutic**

Consideration will need to be given as to whether the samples to be collected are to be used for research purposes or to develop a therapeutic product. A therapeutic product must maintain both a sterile chain and a traceability pathway from sample harvesting right through to patient administration of the final product. As such, samples will generally need to be collected in the clinical area such as an operating theatre or interventional radiology suite (as opposed to being collected in a pathology area). The following SOPs have been developed with this in mind.

If samples are only to be used for research purposes a sterile chain is not required (although a clean chain is still recommended). These protocols can therefore be amended accordingly

#### **Tissue type and quantity**

Broadly speaking tissue samples can be classed as either samples which are surplus to diagnostic purposes, or samples where tissue architecture must be preserved

Samples which are surplus to diagnostic purposes include cases where tissue samples can be taken at the time of surgery which are not required by the pathology team. Generally this will be cases where there is extensive disease at the time of surgery or at the time of recurrence when assessment of surgical margins is not important.

In contrast, for small tumours or for all cancers where the assessment of surgical margins is important the tissue architecture must be preserved at the time of surgery to allow the pathology team to undertake the necessary assessment of the tumour. We have demonstrated that tissue collection and TIL extraction and expansion is possible in this situation but



## Division of Cancer Sciences

SOPs have been generated for both scenarios and it is the role of the tumour collecting team to liaise with the clinical team to assess which situation applies to the tissue type in question.

### Locations of clinical teams

Whilst all non surgical oncology is delivered from the Christie hospital surgery may take place in one more different trusts. Details of these and where surgery takes place by cancer site is listed at [doc2](#). Individual SOPs may need to be generated for each trust.

### Generating a project specific SOP

The following SOPs have been generated as templates which can be modified for any planned project.

Any given tissue collection project is likely to need three SOPs to be adapted for use; a clinical SOP to cover patient identification, recruitment and consent, a tissue collection SOP to cover tissue accrual and initial tissue handling, and a tissue processing SOP to cover the laboratory processing of the tissue once collected.

Finally a data handling SOP may also be required depending on the needs of the specific project.



## Division of Cancer Sciences

### SOP templates and index to other files

File name	description	Location
<b>Clinical SOPs</b>		
Provision of services	Description of location of services in GM by cancer type and notes on regulatory processes already in place	Doc 2
Clinical SOP development	How to map the patient pathway	Doc 3
Biobanking consent	SOP template for gaining consent for patients to contribute to biobank	Doc 4
Ovarian cancer	SOP suitable for use with ovarian cancer patients	Doc 5
Breast cancer	SOP suitable for use with breast cancer patients	Doc 6
Hepatobiliary cancers	SOP suitable for use with hepato biliary cancers including those with oligometastatic colorectal cancers	Doc 7
Neuro cancers	SOP suitable for use with neuro cancer patients	Doc 8
<b>Tissue collection SOPs</b>		
Surplus to requirements	Generalized Tissue Collection Where tissue, surplus to requirement, is available and can be collected without effecting standard of care	Doc 9
Preservation of tissue architecture	Generalized Tissue Collection where tissue microarchitecture must be preserved to protect the standard of care	Doc 10
<b>Tissue Processing SOPs</b>		
TIL from ovarian tumours		Doc 11
<b>Data Handling SOP</b>		
Data management		Doc 12

